PCSK9 and Hypercholesterolemia: Due to this correlation, peripheral PCSK9 inhibition with monoclonal antibodies is an established therapy to reduce the plasma cholesterol level in patients suffering from hypercholesterolemia by increasing the LDL receptor density at the cell surface [27].